cagrilintide semaglutide New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial) In the REDEFINE 2 phase
Description
Overview of Intestinal Mucosal Structure and Barrier Function The intestinal mucosal surface is an essential portal of entry of nutrients, ions, and fluids into the body that is comprised of multiple epithelial cell types serving diverse functions, connected by intercellular junctions, a luminal layer composed of glycocalyx, secreted mucus, water, and ions, and a subepithelial layer comprised of subepithelial nerves, vessels, immune cells, and lymphatics
2012 May;47(1):144-9
KPV derives from a hormone that contributes to skin pigmentation
They also promote recovery from injuries and illnesses
